Atrys Health (ATRY.MC) Stock Price

Atrys Health Price

BME·CLOSED
2.73
​
Market closed

Revenue has compounded at 45.5% per year over the past 13 years to 141.01 M EUR. Earnings per share have declined at 37.2% per year over the last 6 years. Atrys Health's net margin stands at -71.1%, down from -19.2% several years earlier. Analysts set a median price target of 5.76 EUR, implying 111.1% above the current price. Of 10 analysts, 9 rate the stock a buy — an overall Buy consensus.

Atrys Health stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Atrys Health business model & stock analysis

Atrys Health SA is a leading provider of medical services, founded in 2007 in Madrid, Spain, as a spin-off company of the Clinica Universidad de Navarra. The company's goal is to connect the limitless world of science and technology with the human component of healthcare. The business model of Atrys Health specializes in the development of products, services, and solutions in the field of medical imaging and cancer treatment. The company offers innovative technologies and medical services to help diagnose and treat patients better. Atrys Health consists of different business divisions focusing on the needs of clinical practice, research and development, and biotechnological production. The company aims to improve the efficiency and effectiveness of diagnosis, imaging, and treatment technologies to maximize results. The divisions of Atrys Health focus on various aspects of healthcare, including telemedicine, radiology, and proton therapy. Telemedicine provides a platform for remote treatments and medical consultation, improving access to specialists and enabling fast and effective diagnosis and treatment. The radiology division operates diagnostic centers specializing in medical imaging, equipped with the latest imaging technologies. The proton therapy division operates a proton therapy center in Madrid, offering advanced cancer treatment. Atrys Health offers a range of products tailored to the needs of clinical practice, research and development, and biotechnological production. Their key products include Atrilab, a leading platform for precision oncology diagnostics, Auriculum, a technology for precise radiation in cancer treatments, and Vida Oncology, a software solution for cancer treatment management. In conclusion, Atrys Health is a key player in medical imaging and cancer treatment, improving healthcare globally with advanced technologies and services. With their vision of combining innovative technologies with the human component of healthcare, Atrys Health will continue to lead in the healthcare industry.

Frequently asked questions about Atrys Health

The business model of Atrys Health SA revolves around providing advanced medical services and solutions. Atrys is a leading medical technology company that offers specialized diagnostic and therapeutic services, particularly in the fields of oncology, radiology, and molecular medicine. They utilize cutting-edge technology and expertise to deliver accurate diagnoses and personalized treatments to patients. Atrys operates through a network of clinics, laboratories, and telemedicine platforms, ensuring accessibility and quality healthcare solutions. With a focus on precision medicine and innovation, Atrys Health SA aims to improve patient outcomes and contribute to the advancement of the medical field.

Atrys Health SA is primarily active in the healthcare industry.

The main competitors of Atrys Health SA in the market include [Competitor 1], [Competitor 2], and [Competitor 3]. These competitors offer similar products and services, which can create a competitive landscape for Atrys Health SA. However, Atrys Health SA stands out with its unique offerings, such as [mention a unique feature or service]. By maintaining its competitive edge and constantly innovating, Atrys Health SA remains a prominent player in the market, outshining its rivals and ensuring its continued success.

Atrys Health SA is a prominent healthcare company with a rich history and background. Founded in 2008, Atrys Health specializes in medical diagnostic services and telemedicine solutions. With a focus on personalized medicine, the company employs advanced technology and innovative approaches to improve patient care and outcomes. Atrys Health has established a solid reputation in the market by providing high-quality medical services to both public and private institutions. Through strategic partnerships and acquisitions, the company has expanded its operations internationally, becoming a global leader in the field. Atrys Health SA is committed to enhancing healthcare accessibility and efficiency, making significant contributions to the medical industry.

Atrys Health SA, a leading healthcare company, has achieved several significant milestones. It has successfully expanded its reach and offerings, establishing a strong global presence. The company has pioneered advanced medical solutions, leveraging state-of-the-art technology and innovative healthcare practices. Atrys Health SA has consistently focused on delivering excellent patient outcomes, offering personalized diagnostic and treatment services. Its commitment to research and development has led to groundbreaking advancements in areas like molecular diagnostics and telemedicine. With a strong emphasis on collaboration and partnerships, Atrys Health SA continues to revolutionize the healthcare industry, improving access to high-quality medical services worldwide.

Atrys Health SA is primarily present in Spain and several other countries in Europe and Latin America.

Atrys Health SA represents values of excellence, innovation, and patient-centricity. With a dedicated focus on providing advanced medical solutions, Atrys Health combines cutting-edge technology with the expertise of highly skilled professionals. Their corporate philosophy revolves around delivering high-quality healthcare services, improving patient outcomes, and enhancing overall well-being. Atrys Health prioritizes integrity, transparency, and ethical practices in every aspect of their operations. By continuously investing in research and development, Atrys Health aims to revolutionize the healthcare industry and become a global leader in personalized medicine and telemedicine solutions.

Analysts currently set an average price target of 5.81 EUR for the Atrys Health stock (median: 5.76 EUR), implying +113.0 % versus the latest price. The consensus is based on 10 analyst ratings.

10 analysts currently rate the Atrys Health stock: 9 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Atrys Health to generate revenue of 151.69 M EUR and earnings per share of 0.01 EUR.

The Atrys Health share (ATRY.MC) is listed on 3 stock exchanges, including: Frankfurt (A2T.F), Madrid (ATRY.MC).

Atrys Health SA is a leading European healthcare company that provides innovative solutions in the field of precision medicine. The company operates in various sectors, including diagnostics, oncology, radiotherapy, and telemedicine. Atrys Health aims to find new ways to improve healthcare by using groundbreaking technology and scientific knowledge. Answer: Atrys Health SA is a leading European healthcare company that provides innovative solutions in the field of precision medicine. The company operates in various sectors, including diagnostics, oncology, radiotherapy, and telemedicine. Atrys Health aims to improve healthcare by using groundbreaking technology and scientific knowledge.

The expected revenue of Atrys Health is 151.69 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Atrys Health is 881,165.40 EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Atrys Health is currently 235.26. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Atrys Health stock.

The price-to-sales ratio (P/S) of Atrys Health is currently 1.37. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Atrys Health stock.

The Eulerpool Quality Score for Atrys Health is 3/10.

The ISIN of Atrys Health is ES0105148003. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Atrys Health is A2JJ74. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Atrys Health is ATRY.MC. The ticker symbol is used to trade Atrys Health shares on the stock exchange.

Fair ValueTerminal
2.51 EUR
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Providers & Services
Number of shares
Employees
Revenue per Employee
940,046.67 EUR
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
EUR
Initial public offering
Jul 22, 2016
ISIN
ES0105148003
Cusip
E0728U109
Sedol
BD1X3D2
Market capitalization
207.29 M EURMicro Cap
52-Week Range
PEG
-0.02
P/E ratio
P/Ee 2026
235.24
P/Ee 2027
34.83
P/Ee 2028
20.16
P/Ee 2029
—
P/S
P/Se
1.37
EV/EBIT
—
P/B Ratio
1.36
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-24.48 %
Last updated Nov 17, 2026, 3:45 AM

Atrys Health Peer Group

Atrys Health Ticker

BME · ATRY.MCFRANKFURT · A2T.FMADRID · ATRY.MC

Atrys Health FIGI

ATRY:SM · BBG00DF55HM6ATRY:SQ · BBG00DF55HT9ATRYE:L3 · BBG00JPY8T13ATRYE:B3 · BBG00JPY8WR8ATRYE:PO · BBG00JPY9024ATRYEUR:XB · BBG00JPZFRP0ATRYEUR:XS · BBG00JPZFS41ATRYE:L1 · BBG00Y7BF1J4A2T:GR · BBG011VH00B1A2T:GF · BBG011VH00C0A2T:GS · BBG011VH00G6ATRYE:EB · BBG0176D5N66

All fundamentals and in-depth analysis of Atrys Health

Our stock analysis for Atrys Health stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Atrys Health. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.